Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
0.740
-0.090 (-10.84%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Werewolf Therapeutics Employees
Werewolf Therapeutics had 46 employees as of December 31, 2024. The number of employees decreased by 1 or -2.13% compared to the previous year.
Employees
46
Change (1Y)
-1
Growth (1Y)
-2.13%
Revenue / Employee
n/a
Profits / Employee
-$1,559,538
Market Cap
35.96M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 46 | -1 | -2.13% |
| Dec 31, 2023 | 47 | 1 | 2.17% |
| Dec 31, 2022 | 46 | 7 | 17.95% |
| Dec 31, 2021 | 39 | 15 | 62.50% |
| Dec 31, 2020 | 24 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| NextCure | 40 |
| Actinium Pharmaceuticals | 25 |
| INmune Bio | 21 |
| Veru Inc. | 20 |
| RenovoRx | 17 |
| Sensei Biotherapeutics | 15 |
| CervoMed | 15 |
HOWL News
- 4 weeks ago - Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 2 months ago - Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives - GlobeNewsWire
- 4 months ago - Werewolf Therapeutics Announces Pipeline and Business Updates - GlobeNewsWire
- 6 months ago - Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting - GlobeNewsWire
- 6 months ago - Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer - GlobeNewsWire
- 7 months ago - Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting - GlobeNewsWire
- 8 months ago - Werewolf Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference - Transcripts